Drug
PCSK9 Inhibitor clinical trials
Keep track of what changes. Save the PCSK9 Inhibitor studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
21 studies that test it; most in 2026 (5)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 21
Seoul National University Hospital (2) · National Medical Research Center for Therapy and Preventive Medicine (1) · NYU Langone Health (1) · Beijing Anzhen Hospital (1) · Assiut University (1) · West China Hospital (1) · Nanfang Hospital, Southern Medical University (1) · Hanyang University Seoul Hospital (1)
Often tested with
Tested in the same studies.
Hydroxymethylglutaryl-CoA Reductase Inhibitors (3) · Ezetimibe (2) · Pitavastatin (1) · Rosuvastatin (1) · Probucol (1)
Studies
Open first, then newest update. How each study uses PCSK9 Inhibitor is read from its arms, and is right about nine times in ten.
Testing it · 21
- Aggressive Lipid Lowering Therapy in ICI-Treated MelanomaRecruitingNot applicableUniversity of Colorado, DenverNCT07704918Written as Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran)
- Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion StrokeRecruitingNot applicableSeoul National University HospitalNCT06649240Written as PCSK9 inhibitor
- Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors With Statin for ACS PatientsNot yet recruitingPhase 3Assiut UniversityNCT07736313Written as PCSK9 inhibitor plus rosuvastatin 20 mg tab
- The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic PlaquesRecruitingPhase 4General Hospital of Shenyang Military RegionNCT03753555Written as PCSK9 inhibitor
- Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical OutcomeRecruitingNot applicableNanjing First Hospital, Nanjing Medical UniversityNCT05397405Written as PCSK9 inhibitor
- Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon AdenocarcinomaRecruitingPhase 2Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityNCT07468630Written as Tolecizumab (PCSK9 Inhibitor)
- Very Early PCSK9 Inhibition for Acute Myocardial InfarctionRecruitingNot applicableShanghai Zhongshan HospitalNCT07208006Written as Early Intensive Lipid-Lowering Therapy (PCSK9 Inhibitor)
- PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS)Not yet recruitingNot applicableWest China HospitalNCT06791031Written as PCSK9 inhibitor (PCSK9i)
- PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular TherapyNot yet recruitingPhase 2/3Nanfang Hospital, Southern Medical UniversityNCT07174375Written as PCSK9 inhibitor
- Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot StudyNot yet recruitingPhase 4Hanyang University Seoul HospitalNCT07084259Written as PCSK9 inhibitor
- Assessing Coronary Non-Culprit Plaque Early with Start of PCSK9 Inhibitors in Acute Myocardial Infarction (ACCESS-AMI)Not yet recruitingNot applicableYun Dai ChenNCT06854523Written as PCSK9 inhibitor
- Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting (PANDA VIII)Not yet recruitingNot applicableNanjing Medical UniversityNCT06730802Written as PCSK9 inhibitor
- Effect of PCSK9 Inhibitors on Coronary Atherosclerotic Plaques Derived From Optical Coherence TomographyRecruitingPhase 4First Affiliated Hospital of Xinjiang Medical UniversityNCT06520904Written as PCSK9 inhibitor
- Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO)RecruitingPhase 4Lin ZhaoNCT05623995Written as PCSK9 inhibitor
- Exploratory Research of PCSK9 Inhibitor on Patency of aAVF After PTA With PCBRecruitingNot applicableRenJi HospitalNCT06034691Written as pcsk9 inhibitor
- Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant PatientsActive, not recruitingPhase 4National Medical Research Center for Therapy and Preventive MedicineNCT05537948Written as PCSK9 inhibitor
- CHOlesterol Lowering and Residual Risk in Type 2 DiabetesCompletedPhase 4NYU Langone HealthNCT04369664Written as PCSK9 inhibitor
- Acute Myocardial Infarction and Unstable Angina Patients With PCSK9 Inhibitor Usage StudyStatus unknownNot applicableShenzhen People's HospitalNCT04730648Written as PCSK9 inhibitor
- Low-dose PCSK9 Inhibitor Combined With Stains on Serum Lipids in Chinese Population With Acute Coronary SyndromeStatus unknownPhase 4The First Affiliated Hospital with Nanjing Medical UniversityNCT05298475Written as PCSK9 inhibitor
- Impact of PCSK9 Inhibitors on Coronary Plaque Composition and Vulnerability Assessed by Optical Coherence TomographyCompletedPhase 4Beijing Anzhen HospitalNCT04851769Written as PCSK9 inhibitor plus statin